Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Intra-Cellular Therapies revenue
Intra-Cellular Therapies's revenue is $680.9 million.
What is Intra-Cellular Therapies's revenue?
- Intra-Cellular Therapies's revenue growth from 2012 to 2024 is 21,736.24%.
- Intra-Cellular Therapies has 73 employees, and the revenue per employee ratio is $9,326,739.
- Intra-Cellular Therapies's peak quarterly revenue was $199.2M in 2024(q4).
- Intra-Cellular Therapies peak revenue was $680.9M in 2024.
- Intra-Cellular Therapies annual revenue for 2023 was 464.4M, 85.51% growth from 2022.
- Intra-Cellular Therapies annual revenue for 2024 was 680.9M, 46.62% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Intra-Cellular Therapies historical revenue
Intra-Cellular Therapies's peak revenue was $680.9M in 2024. The peak quarterly revenue was $199.2M in 2024(q4).
Intra-Cellular Therapies's revenue increased from $3.1m in 2012 to $680.9M currently. That's a 21,736.24% change in annual revenue.
Intra-Cellular Therapies annual revenue
Intra-Cellular Therapies annual revenue over time
| Fiscal year / year | Intra-Cellular Therapies revenue |
|---|---|
| 2012 | $3.1M |
| 2013 | $2.7M |
| 2014 | $577,301 |
| 2015 | $91,364 |
| 2016 | $330,702 |
| 2017 | $245,837 |
| 2019 | $60,613 |
| 2020 | $22.8M |
| 2021 | $83.8M |
| 2022 | $250.3M |
| 2023 | $464.4M |
| 2024 | $680.9M |
How accurately did Intra-Cellular Therapies' revenue projections match actual performance?
Intra-Cellular Therapies annual growth
Intra-Cellular Therapies saw the greatest revenue growth in 2020, when revenue increased by 37,537.14%.
Intra-Cellular Therapies had the lowest revenue growth in 2015, when revenue changed by -84.17%.
Intra-Cellular Therapies annual growth rate over time
| Year | Intra-Cellular Therapies growth |
|---|---|
| 2013 | -12%↓ |
| 2014 | -79%↓ |
| 2015 | -84%↓ |
| 2016 | 262%↑ |
| 2017 | -26%↓ |
| 2019 | -75%↓ |
| 2020 | 37537%↑ |
| 2021 | 267%↑ |
| 2022 | 199%↑ |
| 2023 | 86%↑ |
| 2024 | 47%↑ |
Intra-Cellular Therapies quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Intra-Cellular Therapies quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2012 | - | - | - | $668,936 |
| 2013 | $598,252 | - | $667,955 | $827,531 |
| 2014 | $167,787 | $219,238 | $124,414 | $65,862 |
| 2015 | $3,315 | $57,390 | - | $30,659 |
| 2016 | - | $228,445 | $4,362 | $97,895 |
| 2017 | $95,287 | $114,741 | $30,754 | $5,055 |
| 2020 | $882,615 | $1.9M | $7.4M | $12.5M |
| 2021 | $15.9M | $19.0M | $22.2M | $25.7M |
| 2022 | $35.0M | $55.6M | $71.9M | $87.9M |
| 2023 | $95.3M | $110.8M | $126.2M | $132.1M |
| 2024 | $144.9M | $161.4M | $175.4M | $199.2M |
Intra-Cellular Therapies jobs nearby
Do you work at Intra-Cellular Therapies?
Is Intra-Cellular Therapies transparent about its revenue structure?
Intra-Cellular Therapies financial information
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 73 |
| Date Founded | 2002 |
| Headquarters | New York, New York |
| Number of Locations | 1 |
| Revenue | $680.9M |
| Net Income | -$256,256,000 |
| Gross Proft | $623.9M (2024) |
| PE Ratio | -9.28 |
| Tax Rate | -0.0% |
| Market Capitalization | $693.1M |
| Total Assets | $754,780,000 |
| Ticker | ITCI |
Intra-Cellular Therapies jobs you might like
Intra-Cellular Therapies financing
Intra-Cellular Therapies received early financing of $15.3M on 2013-05-17.
| Series | Round size | Date |
|---|---|---|
| Debt Financing | $15.3M | 05/2013 |
| Secondary Market | $60M | 09/2013 |
| Post Ipo Equity | $121.4M | 03/2015 |
| Post Ipo Equity | $327.4M | 09/2015 |
| Post Ipo Equity | $150M | 10/2017 |
Intra-Cellular Therapies investors
| Investors | Security type |
|---|---|
| Broadfin Capital | Secondary Market |
| Deerfield | Secondary Market |
Intra-Cellular Therapies revenue FAQs
Search for jobs
Intra-Cellular Therapies highest paying jobs
Zippia gives an in-depth look into the details of Intra-Cellular Therapies, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Intra-Cellular Therapies. The employee data is based on information from people who have self-reported their past or current employments at Intra-Cellular Therapies. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Intra-Cellular Therapies. The data presented on this page does not represent the view of Intra-Cellular Therapies and its employees or that of Zippia.
Intra-Cellular Therapies may also be known as or be related to INTRA CELLULAR THERAPIES INC., Intra Cellular Therapies, Intra-Cellular Therapies, Intra-Cellular Therapies Inc, Intra-Cellular Therapies, Inc. and Intracellular Therapies Inc.